The 4 analysts offering 12-month price forecasts for CureVac NV have a median target of 45.37, with a high estimate of 121.61 and a low estimate of 34.99. The median estimate represents a +4.00% increase from the last price of 43.62.
The current consensus among 5 polled investment analysts is to Hold stock in CureVac NV. This rating has held steady since November, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.64
Reporting Date Apr 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.